赛乐西帕

{{Infobox drug
| drug_name =
| INN =
| Verifiedfields = changed
| verifiedrevid = 444391072
| type =
| image = Selexipag.svg
| width =
| alt =
| caption =

| pronounce =
| tradename = Uptravi
| Drugs.com =
| MedlinePlus =
| licence_EU =
| DailyMedID = Selexipag
| licence_US = Selexipag
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = By mouth, intravenous
| class =
| ATCvet =
| ATC_prefix = B01
| ATC_suffix = AC27
| ATC_supplemental =

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =

| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =

| CAS_number_Ref =
| CAS_number = 475086-01-2
| CAS_supplemental =
| PubChem = 9913767
| IUPHAR_ligand = 7552
| DrugBank_Ref =
| DrugBank = DB11362
| ChemSpiderID_Ref =
| ChemSpiderID = 8089417
| UNII_Ref =
| UNII = 5EXC0E384L
| KEGG_Ref =
| KEGG = D09994
| KEGG2_Ref =
| KEGG2 =
| ChEBI_Ref =
| ChEBI = 90844
| ChEMBL_Ref =
| ChEMBL = 238804
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = ACT-293987, NS-304

| IUPAC_name = 2-{4-[(5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
| chemical_formula_ref =
| C=26 | H=32 | N=4 | O=4 | S=1
| SMILES = CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
| StdInChI = 1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
| StdInChI_comment =
| StdInChIKey = QXWZQTURMXZVHJ-UHFFFAOYSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}

赛乐西帕（Selexipag）或司来帕格，通常以优拓比（Uptravi）的品牌销售，是由瑞士制药公司Actelion开发的用于治疗肺动脉高压的药物。司来帕格及其活性代谢物 ACT-333679（或 MRE-269，游离羧酸）是前列环素受体的激动剂，可导致肺循环中的血管舒张。通常用于口服或静脉注射。

不良反应
赛乐西帕的不良反应与静脉用前列环素治疗肺动脉高压的不良反应相似。常见的副作用包括头痛和下巴痛。服用赛乐西帕的人也注意到甲状腺功能亢进症的风险有所增加。

参考文献
外部链接
*
*

• [https://www.chemicalbook.com/ProductChemicalPropertiesCB32454222.htm 赛乐西帕CAS#: 475086-01-2]